About Kiran Mazumdar-shaw
Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, announced in May 2026 that her niece, Claire Mazumdar, will succeed her as the company's leader. Mazumdar-Shaw stated that she had long planned to groom Claire for the role and decided the time had come to announce it because Claire had "earned her stripes." She cited Claire's work building Biocara Therapeutics, including raising capital, obtaining a breakthrough designation for a bispecific antibody, and listing the company on Nasdaq in 2024 as a billion-dollar company. Mazumdar-Shaw said the transition will be gradual, with Claire expected to take over in five years, and that she herself plans to step back into a guiding role rather than an active one. She also stated that family will remain at the board level while professional management drives day-to-day operations.
On the company's financial performance, Mazumdar-Shaw reported that Biocon closed FY26 on a strong note, with Q4 operating revenue at Rs. 4,517 crore, up 10% year-on-year after adjustments. She said the company is now operating as "one unified biopharma entity" with a stronger balance sheet and that the heavy capital investment phase is behind them, with the focus now on improving utilization, expanding margins, and driving return on capital employed. Mazumdar-Shaw described the outlook as "very bullish," citing new product launches, a growing pipeline, and opportunities in biosimilars and GLP-1 therapies. She also noted that the FDA's decision to waive phase three clinical trials for certain biosimilars has reduced development costs by 50% and accelerated product timelines by three to four years. Separately, Mazumdar-Shaw hosted the 25th annual St. Patrick's Day celebration in Bengaluru in her capacity as Honorary Consul General of Ireland, alongside Ireland's Ambassador to India, Kevin Kelly.
Source: AI-verified profile updated from Kiran Mazumdar-shaw's recent appearances.
Browse all interviews →
✨ AI-enhanced transcript with speaker attribution
R
Reporter0:00
To action from the courts, it's been a significant setback for Swiss biotech giant Roche. The Delhi High Court has cleared Indian drugmaker Biocon and its partner Mylan to make and sell their version of breast cancer drug trastuzumab. The court ruled against the Indian regulator and the true drugmakers seeking to block them from the Indian market. Roche, which sells its brand in India at a high price, argued that the products did not comply with the rules that allowed it to market such drugs. A biosimilar is a drug which is similar to a branded biotech drug, so essentially this means that Biocon and Mylan can now sell their cancer drugs. Kiran Mazumdar-Shaw, the Chairman and Managing Director of Biocon, joins us now. Kiran, how do you read the Delhi High Court order, particularly from the extrapolation clause where Roche contested that Biocon did not do the necessary clinical trials?
K
Kiran Mazumdar-Shaw0:49
Well, I welcome the decision by the Delhi High Court. Basically, we believe that they should not have actually gone to the court in the first place, because any concerns that somebody like Roche should have on a regulatory issue should have been actually referred to the regulatory appellate. But having said that, we are now vindicated because up until now, Roche was objecting to a number of things. One was on the extrapolation of other indications. They have been objecting to the package insert and with reference to their data. I think the regulators have basically stated that everything is in order, that we have actually been given permission for everything that Roche contested.
R
Reporter1:39
But Kiran, this is an interim order. How do you anticipate the case to move forward from here?
K
Kiran Mazumdar-Shaw1:47
No, I think this is a very clear order. What we are concerned about is that we are marketing and are allowed to market the product, and also marketed for all the other indications, plus basically use the package inserts. There were a lot of restrictions that Roche was trying to impose on us, and I think we have been vindicated now. I think our whole objective of providing affordable access to this lifesaving drug is now going to be made much easier. We've been marketing the drug since 2014, and thousands of breast cancer patients in our country have benefited from this drug. So I'm glad this judgment now will clear the way to expand the reach to even more patients.
R
Reporter2:36
So Kiran, what is the size of this drug? The market size of this drug, particularly for companies like Biocon and Mylan?
K
Kiran Mazumdar-Shaw2:45
This is a very large market, even in India. I think between Biocon and Mylan, we have a significant market share. This could become between us a hundred crore opportunity in the very near future.
R
Reporter3:05
In other global markets where you have made filings, innovator companies are already filing legal actions. What sort of legal challenges do you anticipate for Biocon as you enter other global markets? What kind of opposition are you expecting?
K
Kiran Mazumdar-Shaw3:23
Well, these are tactics that all companies play when they lose patent protection and when they are seeing the emergence of a competing biosimilar. These are expected kinds of reactions from innovators. I think Roche has been very active in this area. In many markets, they have been falsely spreading wrong information. But these are things to be expected, because this is a kind of unfair trade practice that many companies indulge in to protect their market monopoly. Well, we will see how this plays out.
R
Reporter4:06
Kiran Mazumdar-Shaw, always a pleasure. Thanks very much for joining us and taking us through what the development in the Delhi High Court means for companies like Biocon and Mylan. It is now time.
